Literature DB >> 32024775

Human T-Cell Lymphotropic Virus Type 1 Transactivator Tax Exploits the XPB Subunit of TFIIH during Viral Transcription.

Christophe Martella1, Armelle Inge Tollenaere1, Laetitia Waast1, Benoit Lacombe1, Damien Groussaud1, Florence Margottin-Goguet1, Bertha Cecilia Ramirez1, Claudine Pique2.   

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) Tax oncoprotein is required for viral gene expression. Tax transactivates the viral promoter by recruiting specific transcription factors but also by interfering with general transcription factors involved in the preinitiation step, such as TFIIA and TFIID. However, data are lacking regarding Tax interplay with TFIIH, which intervenes during the last step of preinitiation. We previously reported that XPB, the TFIIH subunit responsible for promoter opening and promoter escape, is required for Tat-induced human-immunodeficiency virus promoter transactivation. Here, we investigated whether XPB may also play a role in HTLV-1 transcription. We report that Tax and XPB directly interact in vitro and that endogenous XPB produced by HTLV-1-infected T cells binds to Tax and is recruited on proviral LTRs. In contrast, XPB recruitment at the LTR is not detected in Tax-negative HTLV-1-infected T cells and is strongly reduced when Tax-induced HTLV-1 LTR transactivation is blocked. XPB overexpression does not affect basal HTLV-1 promoter activation but enhances Tax-mediated transactivation in T cells. Conversely, downregulating XPB strongly reduces Tax-mediated transactivation. Importantly, spironolactone (SP)-mediated inhibition of LTR activation can be rescued by overexpressing XPB but not XPD, another TFIIH subunit. Furthermore, an XPB mutant defective for the ATPase activity responsible for promoter opening does not show rescue of the effect of SP. Finally, XPB downregulation reduces viability of Tax-positive but not Tax-negative HTLV-1-transformed T cell lines. These findings reveal that XPB is a novel cellular cofactor hijacked by Tax to facilitate HTLV-1 transcription.IMPORTANCE HTLV-1 is considered the most potent human oncovirus and is also responsible for severe inflammatory disorders. HTLV-1 transcription is undertaken by RNA polymerase II and is controlled by the viral oncoprotein Tax. Tax transactivates the viral promoter first via the recruitment of CREB and its cofactors to the long terminal repeat (LTR). However, how Tax controls subsequent steps of the transcription process remains unclear. In this study, we explore the link between Tax and the XPB subunit of TFIIH that governs, via its ATPase activity, the promoter-opening step of transcription. We demonstrate that XPB is a novel physical and functional partner of Tax, recruited on HTLV-1 LTR, and required for viral transcription. These findings extend the mechanism of Tax transactivation to the recruitment of TFIIH and reinforce the link between XPB and transactivator-induced viral transcription.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  TFIIH; oncoprotein; promoter opening; retrovirus; transcription

Mesh:

Substances:

Year:  2020        PMID: 32024775      PMCID: PMC7108837          DOI: 10.1128/JVI.02171-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation.

Authors:  Rihab Nasr; Estelle Chiari; Marwan El-Sabban; Renaud Mahieux; Youmna Kfoury; Maher Abdulhay; Victor Yazbeck; Olivier Hermine; Hugues de Thé; Claudine Pique; Ali Bazarbachi
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

2.  Transcription without XPB Establishes a Unified Helicase-Independent Mechanism of Promoter Opening in Eukaryotic Gene Expression.

Authors:  Sergey Alekseev; Zita Nagy; Jérémy Sandoz; Amélie Weiss; Jean-Marc Egly; Nicolas Le May; Frederic Coin
Journal:  Mol Cell       Date:  2017-02-02       Impact factor: 17.970

3.  Double-stranded DNA translocase activity of transcription factor TFIIH and the mechanism of RNA polymerase II open complex formation.

Authors:  James Fishburn; Eric Tomko; Eric Galburt; Steven Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

4.  Time to eradicate HTLV-1: an open letter to WHO.

Authors:  Fabiola Martin; Yutaka Tagaya; Robert Gallo
Journal:  Lancet       Date:  2018-05-10       Impact factor: 79.321

5.  Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells.

Authors:  N Mori; M Fujii; S Ikeda; Y Yamada; M Tomonaga; D W Ballard; N Yamamoto
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

6.  Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells.

Authors:  Benoît Lacombe; Marina Morel; Florence Margottin-Goguet; Bertha Cecilia Ramirez
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

7.  Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells.

Authors:  Noriko Hironaka; Kanako Mochida; Naoki Mori; Michiyuki Maeda; Naoki Yamamoto; Shoji Yamaoka
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

8.  Dynamic interaction of TTDA with TFIIH is stabilized by nucleotide excision repair in living cells.

Authors:  Giuseppina Giglia-Mari; Catherine Miquel; Arjan F Theil; Pierre-Olivier Mari; Deborah Hoogstraten; Jessica M Y Ng; Christoffel Dinant; Jan H J Hoeijmakers; Wim Vermeulen
Journal:  PLoS Biol       Date:  2006-05-09       Impact factor: 8.029

9.  Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.

Authors:  Xiaoping Song; Zhimin Zhao; Xin Qi; Shuai Tang; Qiang Wang; Tianjiao Zhu; Qianqun Gu; Ming Liu; Jing Li
Journal:  Oncotarget       Date:  2015-03-10

10.  HTLV-1 HBZ Protein Resides Exclusively in the Cytoplasm of Infected Cells in Asymptomatic Carriers and HAM/TSP Patients.

Authors:  Greta Forlani; Marco Baratella; Alessandra Tedeschi; Claudine Pique; Steve Jacobson; Roberto S Accolla
Journal:  Front Microbiol       Date:  2019-04-26       Impact factor: 5.640

View more
  2 in total

1.  Topical Treatment of Human Skin and Cultured Keratinocytes with High-Dose Spironolactone Reduces XPB Expression and Induces Toxicity.

Authors:  M Alexandra Carpenter; Michael G Kemp
Journal:  JID Innov       Date:  2021-05-06

Review 2.  Spironolactone and XPB: An Old Drug with a New Molecular Target.

Authors:  Ryan D Gabbard; Robert R Hoopes; Michael G Kemp
Journal:  Biomolecules       Date:  2020-05-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.